Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Olema Pharmaceuticals Inc OLMA

Healthcare Biotechnology
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. It is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Its lead product... see more

Recent & Breaking News (NDAQ:OLMA)

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire June 3, 2025

Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting

GlobeNewswire May 28, 2025

Olema Oncology to Participate in Upcoming Investor Conferences

GlobeNewswire May 21, 2025

Olema Oncology Reports First Quarter 2025 Financial and Operating Results

GlobeNewswire May 13, 2025

Olema Oncology to Participate in Upcoming Investor Conferences

GlobeNewswire May 9, 2025

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 2, 2025

Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025

GlobeNewswire April 25, 2025

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 2, 2025

Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting

GlobeNewswire March 25, 2025

Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

GlobeNewswire March 18, 2025

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 4, 2025

Olema Oncology to Present at the TD Cowen 45th Annual Health Care Conference

GlobeNewswire February 19, 2025

Olema Oncology Appoints Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate Secretary

GlobeNewswire February 18, 2025

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 4, 2025

Olema Oncology to Participate in Upcoming Investor Conferences

GlobeNewswire February 3, 2025

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire January 3, 2025

Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 2, 2025

Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium

GlobeNewswire December 10, 2024

Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor

GlobeNewswire December 9, 2024

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 3, 2024